ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Patient reported outcomes"

  • Abstract Number: 1363 • ACR Convergence 2020

    Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial

    Vibeke Strand1, Gurjit Kaeley2, Martin Bergman3, Dafna Gladman4, Laura Coates5, Peter Hur6, Nina Kim7, Bhumik Parikh6, Patricia Pertel8 and Philip Mease9, 1Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 2University of Florida College of Medicine - Jacksonville, Jacksonville, FL, 3Drexel University College of Medicine, Philadelphia, PA, 4Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 5University of Oxford, Oxford, United Kingdom, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, 7The University of Texas at Austin; Baylor Scott and White Health, Austin, TX, 8Novartis AG, Basel, Switzerland, 9Seattle Rheumatology Associates, P.L.L.C., Seattle, WA

    Background/Purpose: The phase 3 randomized controlled trial FUTURE 5 (NCT02404350) showed the efficacy of secukinumab (SEC) improving clinical signs, symptoms, and radiographic progression in patients…
  • Abstract Number: 1632 • ACR Convergence 2020

    Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry

    Joerg Henes1, Norbert Blank2, Michael Borte3, Ivan Foeldvari4, Gerd Horneff5, Markus Hufnagel6, Tilmann Kallinich7, Birgit Kortus-Goetze8, Catharina Schuetz9, Frank Weller-Heinemann10, Julia Weber-Arden11 and Jasmin Kuemmerle-Deschner12, 1Department of Internal Medicine II, Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, 2Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany, 3ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, 4Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, 5Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 6Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center, Medical Faculty, University of Freiburg, Germany, Freiburg, Germany, 7Charite, Berlin, Germany, 8Division of Nephrology, University of Marburg, Germany, Marburg, Germany, 9Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, 10Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, 11Novartis Pharma GmbH, Nuremberg, Germany, 12University Hospital Tuebingen, Tuebingen, Germany

    Background/Purpose: Autoinflammatory periodic fever syndromes characterized by excessive interleukin(IL)-1ß release and severe systemic and organ inflammation have been successfully  treated with the anti-IL-1ß inhibitor canakinumab.…
  • Abstract Number: 1943 • ACR Convergence 2020

    The Prevalence of Anxiety and Depression in Patients with Giant Cell Arteritis

    Joana Martinho1, André Ponte2, Eduardo Dourado3, Nikita Khmelinskii1, Sara Dias4, Sofia Barreira5, Ana Rita Cruz-Machado1, Carla Macieira1, Vítor Teixeira6, Ana Rodrigues4, Diogo Telles-Correia7, João Eurico Fonseca8 and Cristina Ponte1, 1Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, 2Centro Hospitalar Psiquiátrico de Lisboa, Lisboa, Portugal, Lisbon, Portugal, 3Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, 4EpiDoC Unit, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa (NMS/UNL), Lisbon, Portugal, 5Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, 6Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, 7Serviço de Psiquiatria, Hospital de Santa Maria, CHULN, Lisboa, Portugal, Lisbon, Portugal, 8Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal

    Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis of the elderly causing blindness if left untreated. However, its hallmark treatment with glucocorticoids…
  • Abstract Number: 0152 • ACR Convergence 2020

    Veterans with RA and Gout Identify Their Goals and How They Can Work with Clinicians to Achieve Their Goals

    Swathi Reddy1, Aricca Van Citters2, Rashmi Arora1, Kyawt Shwin1, Lisa Johnson2, Jabeen Ahmad2, Guy Eakin3, Eugene Nelson2, Andreas Reimold1 and Salahuddin Kazi1, 1Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX, 2The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, 3Arthritis Foundation, Atlanta, GA

    Background/Purpose: Understanding patient goals and concerns is essential for aligning treatment decisions with patient preferences and supporting effective patient-clinician partnerships. Yet, little is known about…
  • Abstract Number: 0280 • ACR Convergence 2020

    Compliance and Validation of Patient Reported Outcome Information Collected from Lupus Patients Using a Mobile Application

    Kristy Bell1, Claire Dykas1, Hope Rainey1, Maggy Comberg1, Mary Mora1 and Peter Lipsky1, 1AMPEL BioSolutions LLC., Charlottesville, VA

    Background/Purpose: Patient Reported Outcomes (PROs) can provide critical data in measuring the impact of a disease on an individual as well as the quality of…
  • Abstract Number: 0543 • ACR Convergence 2020

    Exercise Among Older Adults Living with Rheumatic Disease: Physical Activity Habits and Patient Reported Outcomes

    Alexis Ogdie1, Sofia Pedro2, Joshua Baker3, Kaleb Michaud4 and Patricia Katz5, 1University of Pennsylvania, Philadelphia, PA, 2FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, 3Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 4FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita, 5University of California, San Francisco, Novato, CA

    Background/Purpose: Among patients with rheumatic disease, physical activity is important for maintaining health and improving outcomes.  EULAR recommendations suggest at least 30 min of vigorous…
  • Abstract Number: 1018 • ACR Convergence 2020

    Seasonal Variation in the Treat-to-Target Rate of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE): A Cohort Study on Self-reported Data from Smart System of Disease Management (SSDM)

    Lijun Wu1, Zhanyun Da2, Hongzhi Wang3, Jianlin Huang4, Bin Wu5, Henglian Wu6, Fang He7, Fen Wang8, Rong Du9, Linchong Su10, Qiaoqiao Yao11, Rui Wu12, Zhenbin Li13, Xiaohan Wang14, Yuhong Liu9, Chuanjing Li15, Xiaomei Lei16, Minjun Wang17, Hui Xiao17, Yuhua Jia18, Yihong Liu17, Xin Chen17, Shengsong Jia17, Bing Wu18, Yuan Liu17, Fei Xiao18 and Lingli Dong19, 1People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China (People's Republic), 2The affiliated Hospital of Nantong University, Nantong, Jiangsu, China (People's Republic), 3The First Hospital of Jiaxing, Jiaxing, China (People's Republic), 4The sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), 5Chongqing Hospital of Traditional Chinese Medicine, chongqing, Chongqing, China (People's Republic), 6Dongguan Donghua Hospital, Dongguan, Guangdong, China (People's Republic), 7Suining Central Hospital, Suining, Sichuan, China (People's Republic), 8The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China (People's Republic), 9Union Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China (People's Republic), 10Minda Hospital of Hubei Minzu University, Enshi, Hubei, China (People's Republic), 11China Resources Wuhan Iron and Steel General Hospital, Wuhan, Hubei, China (People's Republic), 12The First Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), 13Chinese people ’s liberation army joint service support force 980 hospital, shijiazhuang, Jiangxi, China (People's Republic), 14Anyang district hospital, Anyang, Henan, China (People's Republic), 15Xiaogan Central Hospital of Hubei Province, Xiaogan, Hubei, China (People's Republic), 16Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China (People's Republic), 17Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), 18Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), 19Tongji Hospital Affiliated to Tongji Medical College of HUST, Wuhan, Hubei, China (People's Republic)

    Background/Purpose: Treat-to-Target(T2T) is the main therapeutic strategy for patients with RA and SLE. There has been no report on comparation of seasonal variations on T2T…
  • Abstract Number: 1228 • ACR Convergence 2020

    Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials

    Clifton Bingham III1, Bochao Jia2, Jianmin Wu2, Amanda Quebe2, Carol Kannowski2, Susan Otawa2, Yun-Fei Chen2, Kirstin Griffing2, Dongyi He3 and Dalton Sholter4, 1Johns Hopkins University, Baltimore, MD, 2Eli Lilly and Company, Indianapolis, IN, 3Shanghai Guanghua Hospital, Shanghai, Shanghai, China (People's Republic), 4University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Baricitinib (BARI) improved patient-reported outcomes (PROs) in patients with insufficient response or intolerance to ≥1 tumor necrosis factor inhibitors (TNFi) or other biological disease-modifying…
  • Abstract Number: 1371 • ACR Convergence 2020

    Improvement in Patient-Reported Outcomes for Upadacitinib versus Placebo Among Patients with Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs

    Vibeke Strand1, Filip Van den Bosch2, Roberto Ranza3, Ying Ying Leung4, Edit Drescher5, Apinya Lertratanakul6, Ralph Lippe7, Christopher Saffore6, Patrick Zueger6 and Peter Nash8, 1Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 2Ghent University Hospital, Ghent, Belgium, 3Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlândia, Brazil, 4Department of Rheumatology & Immunology, Singapore General Hospital, Singapore, Singapore, 5Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, 6AbbVie Inc., North Chicago, IL, 7AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 8School of Medicine Griffith University, Brisbane, Queensland, Australia

    Background/Purpose: The efficacy and safety of upadacitinib (UPA), a selective Janus kinase inhibitor, in patients with PsA is under investigation in Phase 3 clinical trials.…
  • Abstract Number: 1685 • ACR Convergence 2020

    Impact of the COVID-19 Pandemic Among Children with Rheumatic Diseases from Around the Globe

    Jonathan Hausmann1, Kevin Kennedy2, Salman Surangiwala3, Maggie Larche4, Karen Durrant5, Rashmi Sinha6 and Emily Sirotich4, 1Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 2McMaster University, Hamilton, Canada, 3Queen’s School of Medicine, Kingston, Canada, 4McMaster University, Hamilton, ON, Canada, 5Autoinflammatory Alliance, San Francisco, CA, 6SJIA Foundation, Cincinnati

    Background/Purpose: Children with rheumatic diseases face unknown risks in the setting of the COVID-19 pandemic.  These children are often immunosuppressed due to their underlying disease…
  • Abstract Number: 1947 • ACR Convergence 2020

    Risk Factors for Anxiety and Depression in Patients with Giant Cell Arteritis

    Joana Martinho1, André Ponte2, Eduardo Dourado3, Nikita Khmelinskii1, Sara Dias4, Sofia Barreira5, Ana Rita Cruz-Machado1, Carla Macieira1, Vítor Teixeira6, Ana Rodrigues4, Diogo Telles-Correia7, João Eurico Fonseca8 and Cristina Ponte1, 1Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, 2Centro Hospitalar Psiquiátrico de Lisboa, Lisboa, Portugal, Lisbon, Portugal, 3Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, 4EpiDoC Unit, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa (NMS/UNL), Lisbon, Portugal, 5Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, 6Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, 7Serviço de Psiquiatria, Hospital de Santa Maria, CHULN, Lisboa, Portugal, Lisbon, Portugal, 8Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal

    Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis affecting patients aged above 50 years. Its clinical manifestations such as headache, jaw claudication…
  • Abstract Number: 2692 • 2015 ACR/ARHP Annual Meeting

    The Patients Evaluation of Pain and Disease Activity As Well As Improvement during One-Year Follow-up on Etanercept Treatment Is Highly Associated to Subjective Factors and Not to Objective Assessments Including Ultrasound

    Hilde Berner Hammer1 and Jon Lampa2, 1Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dep of Medicine, Rheumatology unit, Karolinska Institute, Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Patient reported outcomes (PROs) are important for evaluation of treatment response in patients with rheumatoid arthritis (RA). Ultrasound (US) is a sensitive method for…
  • « Previous Page
  • 1
  • …
  • 41
  • 42
  • 43
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology